6533b863fe1ef96bd12c7d24
RESEARCH PRODUCT
Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.
S. I. S. FattorusoR. De LucaA. GrassadoniaS. EvolaA. SalvatoR. AddeoG. Cicerosubject
Ca 15-3 Cyclophosphamide Elderly woman Metastatic breast cancer Non-pegylated liposomal doxorubicin Quality of lifeTreatment OutcomeDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansBreast NeoplasmsFemaleCyclophosphamideCardiotoxicityAgedPolyethylene GlycolsRetrospective Studiesdescription
Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6- 18.8) and median progression free survival was 5.8 months (95%CI:4.4- 8.6). Hematologic toxicity with neutropenia was the most frequent adverse event , but the treatment was well tolerated maintained a manageable cardiotoxicity. Conclusion. Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and decreases cardiotoxicity
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-04-06 | La Clinica terapeutica |